Diabetic Nephropathy: Pathophysiology, Stages, Diagnosis & Management
Diabetic Nephropathy (DN) — formerly "DM Nephrology" — is the leading cause of end-stage kidney disease (ESKD) globally. It affects ~30–40% of diabetics.
Pathophysiology
- Chronic hyperglycemia → advanced glycation end-products (AGEs), PKC activation, oxidative stress
- Hemodynamic: Afferent/efferent arteriolar dysregulation → glomerular hypertension, hyperfiltration → sclerosis
- Inflammatory: TGF-β, VEGF, MCP-1 → fibrosis, angiogenesis
- Podocyte injury → albuminuria → tubulointerstitial inflammation
Stages (KDIGO / ADA)
| Stage | GFR (mL/min/1.73m²) | Albuminuria (ACR mg/g) | Clinical |
|---|---|---|---|
| 1: Hyperfiltration | >90 | <30 (A1) | Renal enlargement, ↑ GFR |
| 2: Normoalbuminuric DKD | 60–89 | <30 (A1) | Early structural change, no albuminuria |
| 3: Microalbuminuria | 60–89 | 30–299 (A2) | Incipient nephropathy |
| 4: Macroalbuminuria | 30–59 | ≥300 (A3) | Overt nephropathy; ↑ CVD risk |
| 5: ESKD | <15 | Variable | Renal replacement therapy needed |
Diagnosis & Monitoring
- Annual Screening: UACR (spot urine) + eGFR (CKD-EPI)
- Confirm: 2 of 3 abnormal UACR in 3–6 months
- Exclude Non-Diabetic Kidney Disease: Hematuria, active sediment, rapid decline, no retinopathy → consider biopsy
Multifactorial Management (ABCDE)
| Target | Goal | Agents |
|---|---|---|
| A: A1c | <7% (individualized) | SGLT2i, GLP-1 RA, insulin |
| B: Blood Pressure | <130/80 | ACEi/ARB (max tolerated), +CCB/thiazide |
| C: Cholesterol | Statin ± ezetimibe | High-intensity statin if ASCVD/10-yr risk ≥20% |
| D: Diet / Lifestyle | Low Na (<2g), plant-dominant, exercise, smoking cessation | Renal dietitian referral |
| E: ESKD Prep / SGLT2i | SGLT2i if eGFR ≥20 (↓ ESKD 30–40%) | Dapagliflozin, empagliflozin, canagliflozin |
Key Advances
- SGLT2 Inhibitors: Cardio-renal protection independent of glucose
- Finerenone (non-steroidal MRA): ↓ CKD progression in T2D + albuminuria
- GLP-1 RAs: Weight, glucose, albuminuria reduction
Early detection + RAAS blockade + SGLT2i = paradigm shift from "inevitable decline" to "modifiable trajectory."
Kidney Disease - Related Articles
- Kidney Failure: Early Warning Signs and When to Seek Medical Care
- Kidney Stones & Renal Colic: Causes, Symptoms & Relief
- Antiphospholipid Syndrome (APS): Definition, Criteria, and Management
- Understanding Causes of Death in Kidney Failure: A Comprehensive Overview
- Renal Cyst Concerns: When to Seek Medical Assistance
- Rituximab for Kidney Disease: Exploring Potential & Research
- Ultrasound vs. Extracorporeal Shockwave Therapy: Understanding the Differences
